Dr. Arteaga on Key Takeaway Points From the 2012 SABCS

Carlos L. Arteaga, MD
Published: Monday, Dec 10, 2012

Carlos L. Arteaga, MD, director of the Breast Cancer Program at the Vanderbilt-Ingram Cancer Center and the co-director of the San Antonio Breast Cancer Symposium (SABCS), describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

For practicing oncologists, who see patients five days a week, Arteaga hopes that SABCS will provide relevant information on new trends in breast cancer care. If patterns in care need revised, SABCS may provide essential information to induce skepticism and foster progress.

SABCS hopes to provide the latest information on targeted therapies in breast cancer, for clinical investigators. This information is vital for making enlightened decisions on future research, in the following year.

Arteaga hopes scientists will leave the symposium with a better understanding of the key questions in breast cancer biology. This meeting provides insight into clinically relevant areas that will likely benefit this group of individuals a great deal.

<<< View coverage from the 2012 SABCS

Carlos L. Arteaga, MD, director of the Breast Cancer Program at the Vanderbilt-Ingram Cancer Center and the co-director of the San Antonio Breast Cancer Symposium (SABCS), describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

For practicing oncologists, who see patients five days a week, Arteaga hopes that SABCS will provide relevant information on new trends in breast cancer care. If patterns in care need revised, SABCS may provide essential information to induce skepticism and foster progress.

SABCS hopes to provide the latest information on targeted therapies in breast cancer, for clinical investigators. This information is vital for making enlightened decisions on future research, in the following year.

Arteaga hopes scientists will leave the symposium with a better understanding of the key questions in breast cancer biology. This meeting provides insight into clinically relevant areas that will likely benefit this group of individuals a great deal.

<<< View coverage from the 2012 SABCS


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x